Literature DB >> 26261309

Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.

Jian Zhang1, Yen K Lieu2, Abdullah M Ali2, Alex Penson3, Kathryn S Reggio1, Raul Rabadan4, Azra Raza5, Siddhartha Mukherjee6, James L Manley7.   

Abstract

Serine/arginine-rich splicing factor 2 (SRSF2) is an RNA-binding protein that plays important roles in splicing of mRNA precursors. SRSF2 mutations are frequently found in patients with myelodysplastic syndromes and certain leukemias, but how these mutations affect SRSF2 function has only begun to be examined. We used clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease to introduce the P95H mutation to SRSF2 in K562 leukemia cells, generating an isogenic model so that splicing alterations can be attributed solely to mutant SRSF2. We found that SRSF2 (P95H) misregulates 548 splicing events (<1% of total). Of these events, 374 involved the inclusion of cassette exons, and the inclusion was either increased (206) or decreased (168). We detected a specific motif (UCCA/UG) enriched in the more-included exons and a distinct motif (UGGA/UG) in the more-excluded exons. RNA gel shift assays showed that a mutant SRSF2 derivative bound more tightly than its wild-type counterpart to RNA sites containing UCCAG but bound less tightly to UGGAG sites. Thus in most cases the pattern of exon inclusion or exclusion correlated with stronger or weaker RNA binding, respectively. We further show that the P95H mutation does not affect other functions of SRSF2, i.e., protein-protein interactions with key splicing factors. Our results thus demonstrate that the P95H mutation positively or negatively alters the binding affinity of SRSF2 for cognate RNA sites in target transcripts, leading to misregulation of exon inclusion. Our findings shed light on the mechanism of the disease-associated SRSF2 mutation in splicing regulation and also reveal a group of misspliced mRNA isoforms for potential therapeutic targeting.

Entities:  

Keywords:  leukemia; myelodysplastic syndromes; pre-mRNA splicing; serine/arginine-rich proteins; spliceosome

Mesh:

Substances:

Year:  2015        PMID: 26261309      PMCID: PMC4553800          DOI: 10.1073/pnas.1514105112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Initial sequencing and analysis of the human genome.

Authors:  E S Lander; L M Linton; B Birren; C Nusbaum; M C Zody; J Baldwin; K Devon; K Dewar; M Doyle; W FitzHugh; R Funke; D Gage; K Harris; A Heaford; J Howland; L Kann; J Lehoczky; R LeVine; P McEwan; K McKernan; J Meldrim; J P Mesirov; C Miranda; W Morris; J Naylor; C Raymond; M Rosetti; R Santos; A Sheridan; C Sougnez; Y Stange-Thomann; N Stojanovic; A Subramanian; D Wyman; J Rogers; J Sulston; R Ainscough; S Beck; D Bentley; J Burton; C Clee; N Carter; A Coulson; R Deadman; P Deloukas; A Dunham; I Dunham; R Durbin; L French; D Grafham; S Gregory; T Hubbard; S Humphray; A Hunt; M Jones; C Lloyd; A McMurray; L Matthews; S Mercer; S Milne; J C Mullikin; A Mungall; R Plumb; M Ross; R Shownkeen; S Sims; R H Waterston; R K Wilson; L W Hillier; J D McPherson; M A Marra; E R Mardis; L A Fulton; A T Chinwalla; K H Pepin; W R Gish; S L Chissoe; M C Wendl; K D Delehaunty; T L Miner; A Delehaunty; J B Kramer; L L Cook; R S Fulton; D L Johnson; P J Minx; S W Clifton; T Hawkins; E Branscomb; P Predki; P Richardson; S Wenning; T Slezak; N Doggett; J F Cheng; A Olsen; S Lucas; C Elkin; E Uberbacher; M Frazier; R A Gibbs; D M Muzny; S E Scherer; J B Bouck; E J Sodergren; K C Worley; C M Rives; J H Gorrell; M L Metzker; S L Naylor; R S Kucherlapati; D L Nelson; G M Weinstock; Y Sakaki; A Fujiyama; M Hattori; T Yada; A Toyoda; T Itoh; C Kawagoe; H Watanabe; Y Totoki; T Taylor; J Weissenbach; R Heilig; W Saurin; F Artiguenave; P Brottier; T Bruls; E Pelletier; C Robert; P Wincker; D R Smith; L Doucette-Stamm; M Rubenfield; K Weinstock; H M Lee; J Dubois; A Rosenthal; M Platzer; G Nyakatura; S Taudien; A Rump; H Yang; J Yu; J Wang; G Huang; J Gu; L Hood; L Rowen; A Madan; S Qin; R W Davis; N A Federspiel; A P Abola; M J Proctor; R M Myers; J Schmutz; M Dickson; J Grimwood; D R Cox; M V Olson; R Kaul; C Raymond; N Shimizu; K Kawasaki; S Minoshima; G A Evans; M Athanasiou; R Schultz; B A Roe; F Chen; H Pan; J Ramser; H Lehrach; R Reinhardt; W R McCombie; M de la Bastide; N Dedhia; H Blöcker; K Hornischer; G Nordsiek; R Agarwala; L Aravind; J A Bailey; A Bateman; S Batzoglou; E Birney; P Bork; D G Brown; C B Burge; L Cerutti; H C Chen; D Church; M Clamp; R R Copley; T Doerks; S R Eddy; E E Eichler; T S Furey; J Galagan; J G Gilbert; C Harmon; Y Hayashizaki; D Haussler; H Hermjakob; K Hokamp; W Jang; L S Johnson; T A Jones; S Kasif; A Kaspryzk; S Kennedy; W J Kent; P Kitts; E V Koonin; I Korf; D Kulp; D Lancet; T M Lowe; A McLysaght; T Mikkelsen; J V Moran; N Mulder; V J Pollara; C P Ponting; G Schuler; J Schultz; G Slater; A F Smit; E Stupka; J Szustakowki; D Thierry-Mieg; J Thierry-Mieg; L Wagner; J Wallis; R Wheeler; A Williams; Y I Wolf; K H Wolfe; S P Yang; R F Yeh; F Collins; M S Guyer; J Peterson; A Felsenfeld; K A Wetterstrand; A Patrinos; M J Morgan; P de Jong; J J Catanese; K Osoegawa; H Shizuya; S Choi; Y J Chen; J Szustakowki
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

2.  SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D.

Authors:  Massimo Caputi; Alan M Zahler
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

Review 3.  The SR protein family of splicing factors: master regulators of gene expression.

Authors:  Jennifer C Long; Javier F Caceres
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

Review 4.  Carnitine.

Authors:  L L Bieber
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

5.  A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas.

Authors:  Ruimin Huang; Zhigang Xing; Zhidong Luan; Tangming Wu; Xin Wu; Gengxi Hu
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

6.  Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution.

Authors:  G Agrimi; M A Di Noia; C M T Marobbio; G Fiermonte; F M Lasorsa; F Palmieri
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

7.  Specific interactions between proteins implicated in splice site selection and regulated alternative splicing.

Authors:  J Y Wu; T Maniatis
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

8.  SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing.

Authors:  Alan M Zahler; Christian K Damgaard; Jorgen Kjems; Massimo Caputi
Journal:  J Biol Chem       Date:  2003-12-31       Impact factor: 5.157

9.  Protein-protein interactions and 5'-splice-site recognition in mammalian mRNA precursors.

Authors:  J D Kohtz; S F Jamison; C L Will; P Zuo; R Lührmann; M A Garcia-Blanco; J L Manley
Journal:  Nature       Date:  1994-03-10       Impact factor: 49.962

10.  An exonic splicing enhancer offsets the atypical GU-rich 3' splice site of human apolipoprotein A-II exon 3.

Authors:  Pablo Arrisi-Mercado; Maurizio Romano; Andres F Muro; Francisco E Baralle
Journal:  J Biol Chem       Date:  2004-07-07       Impact factor: 5.157

View more
  94 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

3.  A Systematic Evaluation of Methods for Tailoring Genome-Scale Metabolic Models.

Authors:  Sjoerd Opdam; Anne Richelle; Benjamin Kellman; Shanzhong Li; Daniel C Zielinski; Nathan E Lewis
Journal:  Cell Syst       Date:  2017-02-15       Impact factor: 10.304

Review 4.  Therapeutic approaches to treat human spliceosomal diseases.

Authors:  Anthony B DeNicola; Yi Tang
Journal:  Curr Opin Biotechnol       Date:  2019-02-15       Impact factor: 9.740

Review 5.  Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.

Authors:  Jermaine L Jenkins; Clara L Kielkopf
Journal:  Trends Genet       Date:  2017-03-31       Impact factor: 11.639

6.  SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression.

Authors:  Ning Dou; Dong Yang; Shijun Yu; Binghao Wu; Yong Gao; Yandong Li
Journal:  Cell Prolif       Date:  2018-07-24       Impact factor: 6.831

7.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Authors:  Liang Chen; Jia-Yu Chen; Yi-Jou Huang; Ying Gu; Jinsong Qiu; Hao Qian; Changwei Shao; Xuan Zhang; Jing Hu; Hairi Li; Shunmin He; Yu Zhou; Omar Abdel-Wahab; Dong-Er Zhang; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2018-01-27       Impact factor: 17.970

8.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

9.  Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes.

Authors:  Abdullah Mahmood Ali; Yumin Huang; Ronald Feitosa Pinheiro; Fumin Xue; Jingping Hu; Nicholas Iverson; Daniela Hoehn; Diego Coutinho; Jehanzeb Kayani; Brian Chernak; Joseph Lane; Christopher Hillyer; Naomi Galili; Joseph Jurcic; Narla Mohandas; Xiuli An; Azra Raza
Journal:  Blood Adv       Date:  2018-06-26

Review 10.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.